Literature DB >> 8521042

HSV as a gene transfer vector for the nervous system.

J C Glorioso1, M A Bender, W F Goins, D J Fink, N DeLuca.   

Abstract

Gene therapy for diseases of the nervous system requires vectors capable of delivering the therapeutic gene into postmitotic cells in vivo. Herpes simplex virus type 1 is a neurotropic virus that naturally establishes latency in neurons of the peripheral nervous system. Replication defective HSV vectors have been developed; these are deleted for at least one essential immediate early regulatory gene, rendering the virus less cytotoxic, incapable of reactivation, but still capable of establishing latency. Foreign genes can be vigorously expressed from an HSV-based vector in a transient manner in brain and other tissues. Long-term but weak foreign gene expression may be achieved in the nervous system by exploiting the transcriptional control mechanisms of the natural viral latency active promoter. To meet the needs of specific applications, either highly active long-term or regulatable transgene expression will be needed, requiring further studies in order to design the appropriate latency-based promoter systems.

Entities:  

Mesh:

Year:  1995        PMID: 8521042     DOI: 10.1007/bf02907473

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  71 in total

1.  In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1.

Authors:  J Zwaagstra; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

2.  Control of mRNA stability by the virion host shutoff function of herpes simplex virus.

Authors:  A A Oroskar; G S Read
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.

Authors:  W R Sacks; P A Schaffer
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

4.  Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control.

Authors:  S Forss-Petter; P E Danielson; S Catsicas; E Battenberg; J Price; M Nerenberg; J G Sutcliffe
Journal:  Neuron       Date:  1990-08       Impact factor: 17.173

5.  Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain.

Authors:  R Ramakrishnan; D J Fink; G Jiang; P Desai; J C Glorioso; M Levine
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection.

Authors:  E K Wagner; W M Flanagan; G Devi-Rao; Y F Zhang; J M Hill; K P Anderson; J G Stevens
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli.

Authors:  J H Luo; C C Smith; M Kulka; L Aurelian
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

8.  Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.

Authors:  J G Spivack; N W Fraser
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.

Authors:  W Cai; P A Schaffer
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats.

Authors:  W F Goins; L R Sternberg; K D Croen; P R Krause; R L Hendricks; D J Fink; S E Straus; M Levine; J C Glorioso
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  2 in total

Review 1.  Molecular therapies for malignant glioma.

Authors:  Markus Hutterer; Eberhard Gunsilius; Guenther Stockhammer
Journal:  Wien Med Wochenschr       Date:  2006-06

2.  A comparative study of experimental mouse models of central nervous system demyelination.

Authors:  O M Dumitrascu; K R Mott; H Ghiasi
Journal:  Gene Ther       Date:  2014-04-10       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.